Press release
Rapid Influenza Diagnostic Tests Market: Influenza A+B Testing to Account for Major Market Share
As per Persistence Market Research's latest revised industry analysis, the global rapid influenza diagnostic tests market is expected to witness high growth during the forecast period. The market is expected to top US$ 2 Bn by 2031, which reflects a CAGR of around 8.7% for the decade.Request For Free Sample Market Report @ https://www.persistencemarketresearch.com/samples/31040
Influenza is recognized as a major source of illness and mortality in humans, prompting the development and implementation of diagnostics aimed at decreasing the health and economic consequences. Influenza causes serious illness or death, primarily in high-risk people.
With the start of the flu season comes an increase in antibiotic use, elevating the danger of antibiotic resistance in the body. The speedy turn-around times of devices used at point-of-care aid in the preparation of a targeted and successful treatment plan based on test results. Rapid influenza diagnostic tests have a short turnaround time, with some offering results in under 15 minutes. As a result, adoption of rapid influenza diagnostic tests helps prevent over-prescription of antibiotics as well as avoid the core cause of bacterial resistance and its negative consequences.
The current COVID-19 pandemic has also boosted demand for rapid influenza diagnostic tests. When compared to influenza, COVID-19 has a similar illness presentation - both viruses induce respiratory problems. Furthermore, both are spread via touch, droplets, and fomites. COVID-19 patients have been misdiagnosed with influenza in the past, which has increased demand for virus rapid detection kits.
Buy Full Report Now and Get Up to 20% Discount @ https://www.persistencemarketresearch.com/checkout/31040
Emergence of smartphone-based disease screening has increased market revenue. The Human Genome Project and breakthroughs in molecular and biomedical technology have led to the creation of a plethora of assays and technologies useful for the diagnosis and monitoring of influenza infections. These new technologies, which are based on genomic (PCR-based) and proteomic (microarray-based detection) techniques, aid in the discovery of novel influenza viruses. They also allow for improved surveillance and rapid detection of infectious diseases, which presents a good business opportunity for market players.
Key Takeaways from Market Study
By principle, immunochromatographic assays are set hold high share of 66.8% in 2021, expanding at 6.1% CAGR over the forecast period.
By test type, influenza A+B test is expected to hold 79% market share, and is expected to continue growing at similar trend due to its benefits such as simple to use and rapid diagnosis.
By sample, the nasopharyngeal swab segment is expected to 31% market share, and nasopharyngeal aspirate is the second-leading segment, which accounts for 27.5%.
By end user, office-based settings account for nearly 22.5% market share.
By region, North America held 36.6% of the global market share in 2021.
"Rising demand for rapid disease diagnosis, increasing influenza prevalence, and increased research for diagnostic technologies are expected to provide growth opportunities for market players," says an analyst of Persistence Market Research.
Request Customization@ https://www.persistencemarketresearch.com/request-customization/31040
Market Competition
Leading market players are focusing on product approvals and launches as a key growth strategy for global expansion, thereby enhancing their market presence. They are also emphasizing on entering into strategic partnerships with local suppliers and distributors to expand product reach.
In March 2021, Abbott received an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its AlinityTM m Resp-4-Plex molecular assay, which can identify and discriminate SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) all in one test. This test has received CE certification and is available in countries other than the United States.
In February 2020, the FDA granted Quidel an Emergency Use Authorization (EUA) to market its Sofia® 2 Flu + SARS Antigen FIA for the rapid, simultaneous qualitative identification, and characterization of nucleocapsid protein antigens from SARS-CoV-2, influenza A, and influenza B in direct nasopharyngeal (NP) and nasal (NS) swab samples from persons suspected of respiratory viral infection consistent with COVID-19.
In August 2017, Meridian Bioscience, Inc. announced the expansion of its ImmunoCard STAT!® product line with the addition of ImmunoCard STAT! FLU A&B.
Key market players covered by Persistence Market Research include Thermo Fisher Scientific, Hologic, Quidel Corporation, F. Hoffmann-La Roche AG, Abbott Laboratories, Becton Dickinson and Company, Danaher Corporation, Meridian Bioscience, bioMérieux SA, Luminex Corporation, Siemens Healthineers AG, GenMark Diagnostics, Sekisui Diagnostics, LLC altona Diagnostics GmbH, SA Scientific, and ELITech Group.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the rapid influenza diagnostics tests market in its latest study, presenting historical demand assessment of 2016 - 2020 and projections for 2021 - 2031.
The research study is based on the principle (immunochromatographic assays, immunofluorescence assays and nucleic acid amplification test (NAAT)), test type (influenza A test, influenza B test and influenza A+B test), sample (throat swab, nasal swab, nasal aspirate, nasal wash, nasopharyngeal swab, nasopharyngeal aspirate, nasopharyngeal wash and others) and end user (hospitals, diagnostic centers, nursing homes, office-based settings, urgent care centers, retail pharmacy clinics, schools & universities, public health camps and others (cruise ships, correctional facilities, etc.) in seven prominent regions.
Media Contact:
Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353
sales@persistencemarketresearch.com
About Us
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rapid Influenza Diagnostic Tests Market: Influenza A+B Testing to Account for Major Market Share here
News-ID: 2808629 • Views: …
More Releases from Persistence Market Research

Plastic Liner Market to Reach US$ 6.67 Bn by 2030, Expanding at 4.7% CAGR - Pers …
➤ Overview of the Market
The global plastic liner market has gained steady traction across multiple industries due to its cost-effectiveness, versatility, and protective characteristics. Plastic liners are widely used in agriculture, mining, construction, waste management, and packaging industries, where they serve as an essential barrier to prevent leakage, contamination, and material loss. These liners are manufactured using materials such as polyethylene (PE), polypropylene (PP), and PVC, offering superior resistance to…

Returnable Plastic Crate Market to Reach US$ 2,665.1 Million by 2030 Fueled by S …
➤ Overview of the Market
The global returnable plastic crate market is gaining momentum as industries seek cost-effective and sustainable packaging solutions. These crates are widely used for transporting and storing perishable goods, beverages, pharmaceuticals, and industrial products due to their durability, stackability, and reusability. The shift from single-use packaging to eco-friendly alternatives has accelerated the adoption of returnable plastic crates across sectors. The market, valued at US$ 1,820.0 million in…

US Thermal Power Market Expected to Reach US$ 251.9 Mn by 2031 with 2.4% CAGR Gr …
➤Overview of the Market
The US thermal power market plays a crucial role in the nation's energy mix, serving as a stable and reliable source of electricity despite the rise of renewables. Thermal power plants in the US rely primarily on coal, natural gas, and oil to generate electricity, with natural gas emerging as the dominant fuel source due to its affordability, efficiency, and lower carbon footprint compared to coal. According…

Europe Medical Plastic Market to Reach US$ 17 Bn by 2032 Driven by Rising Health …
➤Overview of the Market
The Europe medical plastic market is undergoing robust growth, fueled by increasing demand for lightweight, durable, and cost-effective materials in the healthcare sector. Medical plastics are widely used in devices, surgical instruments, diagnostic tools, implants, and packaging due to their high biocompatibility, versatility, and resistance to sterilization methods. With healthcare systems across Europe investing heavily in modernization and patient safety, the adoption of medical-grade plastics has gained…
More Releases for SARS
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Market Outlook 20 …
Introduction
Severe Acute Respiratory Syndrome (SARS) is a viral respiratory illness caused by a coronavirus (SARS-CoV). The outbreak of SARS in 2002-2003 marked the world's first encounter with a highly transmissible coronavirus capable of causing severe morbidity and mortality. While SARS was contained, subsequent coronavirus outbreaks, including Middle East Respiratory Syndrome (MERS) and COVID-19 (SARS-CoV-2), highlighted the urgent global need for rapid diagnostics, vaccines, and antiviral therapeutics targeting coronaviruses.
Today, the SARS…
Existing Drugs May Inhibit SARS-CoV-2 Virus
The COVID-19 pandemic has caused more than 600,000 deaths in the United States since the start of 2020 and more than 4 million globally. The search for effective treatments against the disease are ongoing, and one hurdle is that SARS-CoV-2, the virus that causes COVID-19, has a number of tricks up its molecular sleeve when it comes to infecting people.
In a recent study published in Nature Communications Biology, researchers from…
trenzyme GmbH offers recombinant SARS-CoV-2 S1 protein to support Coronavirus re …
The 2019 novel coronavirus SARS-CoV-2 has caused an outbreak of the respiratory illness COVID-19 that started in China and has now spread throughout the world. Meanwhile, the spread of coronavirus has a strong impact on our daily life and the World Health Organization (WHO) has declared a global health emergency to gather resources to fight against this threat.
To support SARS-CoV-2 research, trenzyme offers off-the-shelf recombinant protein of the receptor…
Severe Acute Respiratory Syndrome (SARS) Coronavirus infections : Is there any l …
Worldwide Market Reports adds "Severe Acute Respiratory Syndrome (Sars) Coronavirus Infection Market 2020 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2027" reports to its database.
This report provides in depth study of "Severe Acute Respiratory Syndrome (Sars) Coronavirus Infection Market" using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organisation. The Severe Acute Respiratory Syndrome (Sars) Coronavirus Infection Market report also provides an in-depth survey of…
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.
Severe acute respiratory syndrome (SARS) is a serious, potentially…
Severe Acute Respiratory Syndrome (SARS) pipeline landscape- MRH Report
MRH is working on Pharmaceuticals and Preparing a Research Reports. In this Report 'Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017", provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.
Request a Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1038210
Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family.…